Skip to content

Bruker Corp

US · BRKR #1504 by market cap Listed 1970
56.46 -5.64 -9.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 13 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.1 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
95.28% +0.15pp
Institutions
509 +13
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund77.06%
Individual/Insider31.82%
Hedge Fund11.29%
Public Company3.11%
Government Pension Fund2.46%
Private Company0.83%
Sovereign Wealth Fund0.25%
Insurance Company0.14%

Top holders as of 2026-08-15

Frank Laukien 26.47% · 40.42M sh
Orbis Investment Management Limited 11.75% · 17.94M sh
FMR 9.94% · 15.17M sh
BlackRock 7.72% · 11.79M sh
Pallas Capital Advisors LLC 6.21% · 9.48M sh
Joerg Laukien 4.92% · 7.52M sh
Strategic Advisers LLC 3.35% · 5.12M sh
Vanguard Portfolio Management, LLC 3.26% · 4.97M sh
Vanguard Capital Management, LLC 3.18% · 4.86M sh
Sculptor Capital Management, Inc. 3.03% · 4.63M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 26 buys · 23 sells

NameRoleStake
Frank Laukien Chairperson & CEO 26.47%
Joerg Laukien Former Director 4.92%
Juergen Srega President of Bruker Biosystems Group & Bruker Daltonics Division 0.10%
Mark Munch Corporate Executive VP & President of Bruker Nano Group 0.06%
Richard Packer Director 0.06%
Gerald Herman Chief Financial Officer 0.04%
William Linton Independent Director 0.04%
John Ornell Independent Director 0.02%
Robert Rosenthal Independent Director 0.02%
Falko Busse Former President of Bruker BioSpin Group 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-14 Mark Munch Corporate Executive VP & President of Bruker Nano Group Derivative Exercise and Sale -2,000 $22.19–52.87
2026-08-16 Wolfgang Pusch -- Open Market Disposition -3,473 $56.90
2026-08-14 Frank Laukien Chairperson & CEO Sale to Issuer -4,760 $57.70
2026-08-14 Frank Laukien Chairperson & CEO Other Acquisition +29,463 --
2026-08-14 Frank Laukien Chairperson & CEO Other Derivative Acquisition +71,651 $63.47
2026-08-14 Mark Munch Corporate Executive VP & President of Bruker Nano Group Sale to Issuer -2,984 $57.70
2026-08-14 Mark Munch Corporate Executive VP & President of Bruker Nano Group Other Acquisition +14,443 --
2026-08-14 Mark Munch Corporate Executive VP & President of Bruker Nano Group Other Derivative Acquisition +11,708 $57.70
2026-08-14 Gerald Herman Chief Financial Officer Sale to Issuer -2,724 $57.70
2026-08-14 Gerald Herman Chief Financial Officer Other Acquisition +15,794 --
2026-08-14 Gerald Herman Chief Financial Officer Other Derivative Acquisition +12,803 $63.47
2026-08-14 Burkhard Prause President and CEO of Bruker Energy & Supercon Technologies, Inc. Other Acquisition +3,303 --
2026-08-14 Burkhard Prause President and CEO of Bruker Energy & Supercon Technologies, Inc. Other Derivative Acquisition +2,678 $57.70
2026-08-14 Juergen Srega President of Bruker Biosystems Group & Bruker Daltonics Division Other Acquisition +16,898 --
2026-08-14 Juergen Srega President of Bruker Biosystems Group & Bruker Daltonics Division Other Derivative Acquisition +13,698 $57.70
2026-08-14 Thomas Bures Chief Accounting Officer Other Acquisition +4,035 --
2026-08-14 Wolfgang Pusch -- Other Acquisition +3,120 --
2026-08-14 Wolfgang Pusch -- Other Derivative Acquisition +2,529 $57.70
2026-08-13 Mark Munch Corporate Executive VP & President of Bruker Nano Group Derivative Exercise and Sale -2,000 $22.19–57.60
2026-08-10 Frank Laukien Chairperson & CEO Sale to Issuer -4,838 $57.02

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.

Bruker Corp discussion 0 comments

Add a comment